Related Experiment Video
Updated: Jul 6, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a
Trino Baptista1, Euderruh Uzcátegui, Nairy Rangel
1Department of Physiology, Los Andes University Medical School, P.O. Box 93, Mérida, 5101-A, Venezuela. trinbap@yahoo.com
Abstract:
Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients. Weight loss was similar in both groups: -2.8+/-3.2 kg vs. -1.4+/-2.6 kg. Except for preventing a triglyceride increase, the drug combination lacked efficacy for metabolic control in this clinical population.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antidepressant Drugs: MAOIs and Other Agents
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Psychosis: Goals of Pharmacotherapy
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients